top of page

Exploratory/Developmental Grants Related to the World Trade Center Survivors (R21-No Applications with Responders Accepted)

HHS-CDC-HHSCDCERA

Status:

Forecasted

April 25, 2023

Posted:

Deadline: 

December 5, 2023

Funding

4000000

Program:

200000

Award Floor:

Ceiling:

500000

Match Required?

No

Eligibility

All

States:

Entity Types:

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public & State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations, Nonprofits (with 501(c)(3) status), Nonprofits (without 501(c)(3) status)

Bona Fide Agents: A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with "Other Attachment Forms".Federally Funded Research and Development Centers (FFRDCs): FFRDCs are operated, managed, and/or administered by a university or consortium of universities, other not-for-profit or nonprofit organization, or an industrial firm, as an autonomous organization or as an identifiable separate operating unit of a parent organization. A FFRDC meets some special long-term research or development need which cannot be met as effectively by an agency's existing in-house or contractor resources. FFRDC's enable agencies to use private sector resources to accomplish tasks that are integral to the mission and operation of the sponsoring agency. For more information on FFRDCs, go to https://gov.ecfr.io/cgi-bin/searchECFR.

Contact

Email:

Phone:

Source Type:

Federal

NIOSH supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 Health and Compensation Act of 2010 (Public Law 111347, as amended by Public Laws 114113 and 11659).To help address the Zadroga Act research mandate, as supported by the World Trade Center (WTC) Health Program in consultation with the WTC Health Program Scientific/Technical Advisory Committee, NIOSH is soliciting applications for scientifically rigorous research (42 U.S.C. 300mm51) among enrolled certified-eligible WTC survivors and similarly exposed populations in New York City in Manhattan between Houston Street and 14th Street and in Brooklyn to help answer critical questions about:Physical and mental health conditions that may be related to the September 11, 2001, terrorist attacks;Diagnosing WTC-related health conditions for which there has been diagnostic uncertainty; andTreating WTC-related health conditions for which there has been treatment uncertainty.A major area of research interest of this announcement also includes improving the healthcare and well-being of at-risk survivor populations including minority groups, women exposed while pregnant or of reproductive age, the elderly, adolescents, and other minor children.Certified-eligible WTC survivors (adults and children) include individuals who lived, worked, went to school, or attended child or adult day care in the New York City (NYC) Disaster Area, as defined in 42 CFR 88.1, on September 11, 2001, or in the following days, weeks, or months and those otherwise meeting the eligibility criteria in 42 CFR 88.7 or 88.8 who have been identified as eligible for medical monitoring and treatment as described in 42 CFR 88.1 or 88.12(b).In addition to certified-eligible WTC survivors, proposed research can include sampled populations outside the NYC disaster area in Manhattan as far north as 14th Street and in Brooklyn, along with control populations, to identify potential for long-term adverse health effects in less exposed populations.NIOSH/WTC Health Program R21 grants support the early and conceptual stages of research projects that assess the feasibility of novel areas of investigation, with the potential to enhance the effectiveness of treatment and diagnostic practice. These studies may lead to breakthroughs in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that have a major clinical impact. These studies should break new ground or extend previous discoveries toward new directions or applications. Applicants are expected to propose research approaches for which there is likely to be minimal or no preliminary data.

Tired of searching for grants? Consider a Scouting Report.

bottom of page